Nuformix PLC on Wednesday said that, despite having to wait longer than expected, human disease tissue has now been acquired for its NXP002 programme.

Nuformix is a London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. NXP002 is a new form of tranilast which Nuformix is developing as a novel inhaled treatment for idiopathic pulmonary fibrosis.

The company has already begun studies in 3D human IPF lung tissue using a disease and species relevant model, and is working with its partner, Fibrofind, focusing on NXP002 in combination with current standards of care.

Suitable human disease tissue, which is highly limited in supply, has now been acquired allowing the practical elements of the study to commence, with results and further updates to be announced in due course.

‘We’ve had to wait a little longer than expected to acquire suitable tissue, but I’m delighted that the main element of this key study, further evaluating NXP002 combination therapies is now underway and I look forward to sharing the results when they are available,’ said Executive Director Dan Gooding.

Nuformix shares were trading 5.9% higher at 0.32 pence each in London on Wednesday at noon.

Copyright 2023 Alliance News Ltd. All Rights Reserved.